¼¼°èÀÇ ¾à¹° ÅëÇÕ Æú¸®¸Ó ¼¶À¯ ½ÃÀå : Á¾·ùº°, ¿ëµµº°, Ä¡·á ÀûÀÀÁõº°, ÃÖÁ¾»ç¿ëÀÚº°, ±¹°¡º°, Áö¿ªº° - »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À², ¿¹Ãø(2025-2032³â)
Drug Integrated Polymer Fibers Market, By Type, By Application, By Therapeutic Indication, By End-User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
»óǰÄÚµå : 1684318
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2025³â 03¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 301 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,702,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,728,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 8,174,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

º¸°í¼­ ÇÏÀ̶óÀÌÆ®

¾à¹° ÅëÇÕ Æú¸®¸Ó ¼¶À¯ ½ÃÀåÀº 2024³â 8,598¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç 2025³âºÎÅÍ 2032³â±îÁö CAGR 5.90%·Î È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¾à¹° ÅëÇÕ Æú¸®¸Ó ¼¶À¯ ½ÃÀå ¿ªÇÐ

¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ½ÃÀå ¼ºÀåÀÌ ±â´ëµË´Ï´Ù.

¸ÂÃãÇü ÀÇ·á´Â ȯÀÚ °³°³Àο¡ ƯȭµÈ Ç¥Àû Ä¡·á¸¦ ÃËÁøÇÔÀ¸·Î½á ¾à¹°Àü´Þ¿¡ Çõ¸íÀ» °¡Á®¿ÔÀ¸¸ç, ÀÌ´Â °íºÐÀÚ ±â¹Ý ¾à¹°Àü´Þ ½Ã½ºÅÛÀÇ »ç¿ëÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¾à¹°ÀÌ ³»ÀåµÈ Æú¸®¸Ó ¼¶À¯´Â ¾à¹°ÀÇ Á¦¾îµÈ ¼­¹æÇü ¹æÃâÀ» °¡´ÉÇÏ°Ô ÇÏ¿© °¢ ȯÀÚÀÇ °íÀ¯ÇÑ Çʿ信 µû¶ó Ä¡·á È¿°ú°¡ ÃÖÀûÈ­µÇµµ·Ï º¸ÀåÇÕ´Ï´Ù. 2023³â FDA´Â Èñ±ÍÁúȯ ȯÀÚ¸¦ À§ÇÑ 16°³ÀÇ »õ·Î¿î °³º°È­ Ä¡·áÁ¦¸¦ ½ÂÀÎÇßÀ¸¸ç, ÀÌ´Â 2022³âÀÇ 6°³¿¡¼­ Å©°Ô Áõ°¡ÇÑ ¼öÄ¡ÀÔ´Ï´Ù. °³ÀθÂÃãÀǷῬÇÕÀÇ º¸°í¿¡ µû¸£¸é 2023³â¿¡ »õ·Î ½ÂÀÎµÈ Ä¡·á¹ý Áß ¾Ï Ä¡·áÁ¦°¡ 7°³, ±âŸ Áúº´ ¹× Áõ»ó¿¡ ´ëÇÑ Ä¡·áÁ¦°¡ 3°³·Î ³ªÅ¸³µ½À´Ï´Ù. ±×·³¿¡µµ ºÒ±¸ÇÏ°í ¼¶À¯ Á¦Á¶ ±â¼úÀÇ ¹ßÀüÀº ½ÃÀå¿¡ ¼ºÀå ±âȸ¸¦ °¡Á®¿Ã ¼ö ÀÖ½À´Ï´Ù. ¹Ý´ë·Î ³ôÀº Á¦Á¶ºñ¿ëÀÌ ½ÃÀå È®´ë¸¦ ÀúÇØÇÒ °¡´É¼ºµµ ÀÖ½À´Ï´Ù.

¾à¹° ÅëÇÕ Æú¸®¸Ó ¼¶À¯ ½ÃÀå : ÁÖ¿ä ÀλçÀÌÆ®

¸®¼­Ä¡ ¾Ö³Î¸®½ºÆ®ÀÇ ºÐ¼®¿¡ µû¸£¸é, ¼¼°è ½ÃÀåÀº ¿¹Ãø ±â°£(2025-2032³â) µ¿¾È ¾à 5.90%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

À¯Çüº°·Î´Â Æú¸®¶ôÆ®»ê(PLA)ÀÌ 2024³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¾ú½À´Ï´Ù.

¿ëµµº°·Î´Â Á¤Çü¿Ü°ú¿ë ºÀÇջ簡 2024³â ÁÖ¿ä ¿ëµµÀÔ´Ï´Ù.

Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2024³â ¼öÀÍÀ» âÃâÇÏ´Â ÁÖ¿ä ½ÃÀåÀÔ´Ï´Ù.

¾à¹° ÅëÇÕ Æú¸®¸Ó ¼¶À¯ ½ÃÀå : ¼¼ºÐÈ­ ºÐ¼®

¼¼°è ¾à¹° ÅëÇÕ Æú¸®¸Ó ¼¶À¯ ½ÃÀåÀº À¯Çü, ¿ëµµ, Ä¡·á ÀûÀÀÁõ, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ª¿¡ µû¶ó ¼¼ºÐÈ­µË´Ï´Ù.

½ÃÀåÀº Á¾·ù¿¡ µû¶ó Æú¸®¶ôÆ®»ê(PLA), Æú¸®µð¿Á»ç³í(PDO), Æú¸®Ä«ÇÁ·Î¶ôÅæ(PCL), ±âŸ(PGA, PLGA, PDLL)ÀÇ ¼¼ °¡Áö ¹üÁÖ·Î ³ª´¹´Ï´Ù. Æú¸®¶ôÆ®»ê(PLA)ÀÌ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. Æú¸®¶ôÆ®»ê(PLA)Àº »ýºÐÇØ¼º ¹× »ýüÀûÇÕ¼º °íºÐÀÚÀ̸ç, ¾à¹° ¹æÃâÀ» Á¦¾îÇϱâ À§ÇØ ¼¶À¯, Çʸ§ ¹× ±âŸ ÇüÅ·Π°¡°øÇÒ ¼ö Àֱ⠶§¹®¿¡ ÀÌ ½ÃÀå¿¡¼­ ÀÚÁÖ »ç¿ëµÇ¸ç, PLA´Â ¿Á¼ö¼ö ÀüºÐÀ̳ª »çÅÁ¼ö¼ö¿Í °°Àº Àç»ý °¡´ÉÇÑ ÀÚ¿ø¿¡¼­ À¯·¡ÇÏ¿© ȯ°æ ģȭÀûÀÎ ¼±ÅÃÀÔ´Ï´Ù. ģȯ°æÀûÀÎ ¼±ÅÃÀÔ´Ï´Ù. »ýºÐÇØ¼ºÀÌ Àֱ⠶§¹®¿¡ ü³»¿¡¼­ ¼¶À¯°¡ ¼­¼­È÷ ºÐÇØµÇ¾î ¿Ü°úÀû Á¦°ÅÀÇ Çʿ伺À» ÃÖ¼ÒÈ­ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀåÀº ¿ëµµº°·Î ¾à¹°Àü´Þ, Á¤Çü¿Ü°ú¿ë ºÀÇÕ»ç, Ç÷°ü ½ºÅÙÆ®, Àΰø Ç÷°ü, ÇǺΠ»óó Ä¡À¯, ±âŸ µî 5°¡Áö ¹üÁÖ·Î ³ª´¹´Ï´Ù. Á¤Çü¿Ü°ú¿ë ºÀÇջ簡 ½ÃÀå µ¶Á¡ Á¤Çü¿Ü°ú¿ë ºÀÇÕ»ç °ü·Ã ¾à¹° ÅëÇÕ Æú¸®¸Ó ¼¶À¯ ½ÃÀåÀº Æú¸®¸Ó ¼¶À¯ÀÇ »ýüÀûÇÕ¼º°ú Á¤Çü¿Ü°ú ¿ëµµÀÇ È¿°úÀûÀÌ°í ±¹¼ÒÀûÀÎ ¾à¹°Àü´ÞÀÇ Çʿ伺ÀÌ °áÇյǾî ÀÇ·á±â±â »ê¾÷¿¡¼­ À¯¸ÁÇÏ°í ºü¸£°Ô ¹ßÀüÇϰí ÀÖ´Â ºÐ¾ßÀÔ´Ï´Ù. ¾à¹° ÅëÇÕ Æú¸®¸Ó ¼¶À¯·Î ¸¸µç Á¤Çü¿Ü°ú¿ë ºÀÇÕ»ç´Â ¾à¹°À» ¼ö¼ú ºÎÀ§¿¡ Á÷Á¢ Àü´ÞÇÏ¿© Ä¡À¯¸¦ ÃËÁøÇϵµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù. ÀÌ´Â »À¿Í ¿¬ºÎÁ¶Á÷ÀÇ ÀûÀýÇÑ Ä¡À¯°¡ Àå±âÀûÀΠȸº¹¿¡ ÇʼöÀûÀÎ Á¤Çü¿Ü°ú ¼ö¼ú¿¡¼­ ƯÈ÷ Áß¿äÇÕ´Ï´Ù.

½ÃÀåÀº Ä¡·á ´ë»ó ÀûÀÀÁõ¿¡ µû¶ó ¾Ï, ½ÉÇ÷°üÁúȯ, È£Èí±âÁúȯÀÇ ¼¼ °¡Áö ¹üÁÖ·Î ³ª´¹´Ï´Ù. ±â¼úÀÌ ¹ßÀüÇÔ¿¡ µû¶ó ÀÌ·¯ÇÑ ¼¶À¯´Â ´õ¿í Á¤±³ÇØÁ® ¾à¹° ¹æÃâÀ» Á¦¾îÇÏ°í °³º°È­µÈ Ä¡·á Á¢±Ù¹ýÀ» °¡´ÉÇÏ°Ô ÇÏ¿© ±Ã±ØÀûÀ¸·Î ȯÀÚÀÇ Ä¡·á °á°ú¿Í »îÀÇ ÁúÀ» Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ä¡·á ¿µ¿ª¿¡¼­ ¾à¹°Àü´Þ¿¡ Æú¸®¸Ó ¼¶À¯¸¦ »ç¿ëÇÏ´Â °¡Àå Å« ÀåÁ¡ Áß Çϳª´Â ±¹¼ÒÀûÀ̰í Ç¥ÀûÈ­µÈ Ä¡·á¸¦ Á¦°øÇϰí Àü½Å ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­ÇÒ ¼ö ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. ¾à¹° ÅëÇÕ Æú¸®¸Ó ¼¶À¯ÀÇ °³¹ßÀº ƯÈ÷ »ýüÀûÇÕ¼º, ¾ÈÀü¼º ¹× Àå±âÀû À¯È¿¼º¿¡ ´ëÇÑ ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°ÇÀ» ÃæÁ·ÇØ¾ß ÇÕ´Ï´Ù.

½ÃÀåÀº ÃÖÁ¾»ç¿ëÀÚ¿¡ µû¶ó Á¦¾àȸ»ç¿Í ÀÇ·á±â±â Á¦Á¶¾÷üÀÇ µÎ °¡Áö·Î ºÐ·ùµË´Ï´Ù. ƯÈ÷ Á¦¾àȸ»ç ¹× ÀÇ·á±â±â Á¦Á¶¾÷ü¿Í °°Àº ÃÖÁ¾»ç¿ëÀÚ Ãø¸é¿¡¼­ ¾à¹° ÅëÇÕ Æú¸®¸Ó ¼¶À¯ ½ÃÀåÀº º¸´Ù È¿°úÀûÀ̰í Ç¥ÀûÈ­µÈ Ä¡·á¸¦ À§ÇØ Ã·´Ü ¾à¹°Àü´Þ ±â¼úÀ» ¸ð»öÇϰí Àֱ⠶§¹®¿¡ Å« ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. µÎ »ê¾÷ ¸ðµÎ ȯÀÚ °á°ú¸¦ °³¼±Çϰí Ä¡·á ¿ä¹ýÀ» ÃÖÀûÈ­Çϱâ À§ÇØ ¾à¹° ÅëÇÕ Æú¸®¸Ó ¼¶À¯¸¦ Á¡Á¡ ´õ ¸¹ÀÌ È°¿ëÇϰí ÀÖ½À´Ï´Ù.

¾à¹° ÅëÇÕ Æú¸®¸Ó ¼¶À¯ ½ÃÀå : Áö¿ªº° ºÐ¼®

ºÏ¹Ì°¡ ½ÃÀå È®´ë¸¦ ÁÖµµÇϰí ÀÖÁö¸¸, ±× ÁÖ¿ä ¿äÀÎÀº ½ÅÈï±¹ÀÇ ÀÇ·áºñ Áõ°¡ÀÔ´Ï´Ù. ÀÇ·á ÀÎÇÁ¶ó ¹× ÀÇ·á ¿¬±¸¸¦À§ÇÑ Á¤ºÎ ¹× ¹Î°£ ºÎ¹®ÀÇ ÀÚ±Ý Á¶´Þ Áõ°¡´Â ¾à¹° ÅëÇÕ Æú¸®¸Ó ¼¶À¯ÀÇ ¹ßÀü°ú ±¸ÇöÀ» ÃËÁøÇÒ °ÍÀÔ´Ï´Ù. ¹Ì±¹ ÀÇ»ç ÇùȸÀÇ º¸°í¼­¿¡ µû¸£¸é ¹Ì±¹ÀÇ ÀÇ·áºñ´Â 2022³â 4.1% Áõ°¡ÇÏ¿© 4Á¶ 5,000¾ï ´Þ·¯¿¡ ´ÞÇßÀ¸¸ç ÀÌ´Â ±¹¹Î 1Àδç 1¸¸ 3,493 ´Þ·¯¿¡ ÇØ´çÇÕ´Ï´Ù. ÀÌ ¼ºÀå·üÀº COVID-19 ÀÌÀü ¼öÄ¡, ƯÈ÷ 2019³âÀÇ 4.1%¿Í ÀÏÄ¡ÇÕ´Ï´Ù. ÆÒµ¥¹Í ´ëÀÀÀ» À§ÇÑ Á¤ºÎ ÁöÃâ·Î ÀÎÇØ ±¹¹ÎÀÇ·áºñ(NHE)°¡ Å©°Ô Áõ°¡ÇßÁö¸¸, 2021³â¿¡´Â ÀÌ·¯ÇÑ ºñ¿ëÀÌ ´«¿¡ ¶ç°Ô °¨¼ÒÇßÀ¸¸ç, ÀÌ´Â ÀÇ·á »óǰ ¹× ¼­ºñ½º ÀÌ¿ëÀÌ È¸º¹µÈ °Í°ú ÀÏÄ¡ÇÕ´Ï´Ù. À¯·´Àº ³ª³ë±â¼ú°ú Àü±â¹æ»ç ±â¼ú¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡·Î ÀÎÇØ ½ÃÀå ¼ºÀå·ü 2À§¸¦ Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¾à¹° ÅëÇÕ Æú¸®¸Ó ¼¶À¯ ½ÃÀå : °æÀï »óȲ

¾à¹° ÅëÇÕ Æú¸®¸Ó ¼¶À¯ ½ÃÀåÀº Çõ½ÅÀûÀÎ Á¦Ç°°ú ÷´Ü ¾à¹°Àü´Þ ½Ã½ºÅÛ °³¹ßÀ» ÅëÇØ ½ÃÀå Á¡À¯À²À» È®º¸Çϱâ À§ÇØ ³ë·ÂÇÏ´Â ´Ù¼öÀÇ ¼±µµÀûÀÎ ±â¾÷µé·Î ÀÎÇØ ³ôÀº ¼öÁØÀÇ °æÀïÀ» º¸À̰í ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀåÀº Ç¥Àû ¾à¹°Àü´Þ ¸ÞÄ¿´ÏÁò, ÃÖ¼Òħ½ÀÀû ÀÇ·á±â±â, »ýüÀûÇÕ¼º Àç·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇØ ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ÀÌ ºÐ¾ßÀÇ ±â¾÷µéÀº ¾à¹°ÀÇ »ýüÀûÇÕ¼º°ú È¿´ÉÀ» º¸ÀåÇϸ鼭 Áö¼ÓÀûÀÎ ¾à¹° ¹æÃâÀ» °¡´ÉÇÏ°Ô Çϴ ÷´Ü Æú¸®¸Ó ¼¶À¯ °³¹ß¿¡ Àü³äÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÌµé ±â¾÷Àº Á¦¾àȸ»ç, »ý¸í°øÇÐ ±â¾÷, Çмú ±â°ü°ú Çù·Â °ü°è¸¦ ±¸ÃàÇÏ¿© Á¦Ç° °³¹ß ³ë·ÂÀ» °­È­Çϰí ÷´Ü ±â¼ú¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» È®º¸Çϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¾à¹° ÅëÇÕ Æú¸®¸Ó ¼¶À¯ ½ÃÀå °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¾à¹° ÅëÇÕ Æú¸®¸Ó ¼¶À¯ÀÇ ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå ¾à¹° ÅëÇÕ Æú¸®¸Ó ¼¶À¯ ½ÃÀå : »ê¾÷ ºÐ¼®

Á¦5Àå ¾à¹° ÅëÇÕ Æú¸®¸Ó ¼¶À¯ ½ÃÀå : ³ô¾ÆÁö´Â ÁöÁ¤ÇÐÀû ±äÀåÀÇ ¿µÇâ

Á¦6Àå ¾à¹° ÅëÇÕ Æú¸®¸Ó ¼¶À¯ ½ÃÀå »óȲ

Á¦7Àå ¾à¹° ÅëÇÕ Æú¸®¸Ó ¼¶À¯ ½ÃÀå : Á¾·ùº°

Á¦8Àå ¾à¹° ÅëÇÕ Æú¸®¸Ó ¼¶À¯ ½ÃÀå : ¿ëµµº°

Á¦9Àå ¾à¹° ÅëÇÕ Æú¸®¸Ó ¼¶À¯ ½ÃÀå : Ä¡·á ´ë»ó ÀûÀÀÁõº°

Á¦10Àå ¾à¹° ÅëÇÕ Æú¸®¸Ó ¼¶À¯ ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

Á¦11Àå ¾à¹° ÅëÇÕ Æú¸®¸Ó ¼¶À¯ ½ÃÀå : Áö¿ªº°

Á¦12Àå ÁÖ¿ä º¥´õ ºÐ¼® : ¾à¹° ÅëÇÕ Æú¸®¸Ó ¼¶À¯ ¾÷°è

Á¦13Àå AnalystViewÀÇ Àü¹æÀ§Àû ºÐ¼®

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

The Drug Integrated Polymer Fibers Market was valued at US$ 85.98 million in 2024 and expanded at a CAGR of 5.90% from 2025 to 2032.

Drug Integrated Polymer Fibers are advanced fibers composed of polymers that are infused with therapeutic agents to facilitate controlled and sustained drug release. These fibers are engineered to administer medications directly to targeted areas within the body or to distribute them throughout the system over an extended duration, thereby improving the efficacy and accuracy of medical treatments. Their applications are numerous, particularly within the medical and pharmaceutical sectors, where they serve purposes such as implantable drug delivery systems, wound management, and surgical sutures.

Drug Integrated Polymer Fibers Market- Market Dynamics

Rising Demand for Personalized Medicine is expected to the market growth.

Personalized medicine is revolutionizing drug delivery by facilitating targeted treatments that are specific to individual patients, which in turn is promoting the use of polymer-based drug delivery systems. Polymer fibers that incorporate drugs enable the controlled and sustained release of medications, thereby ensuring that therapeutic effects are optimized according to the unique needs of each patient. In 2023, the FDA approved 16 new personalized treatments aimed at patients with rare diseases, a significant increase from the six approvals in 2022. Among the newly approved treatments for 2023, there are seven drugs for cancer and three addressing other diseases and conditions, as reported by the Personalized Medicine Coalition. Nevertheless, advancements in fiber manufacturing technology may present growth opportunities for the market. Conversely, high manufacturing costs could impede market expansion.

Drug Integrated Polymer Fibers Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 5.90% over the forecast period (2025-2032)

Based on Type segmentation, Polylactic Acid (PLA) was predicted to show maximum market share in the year 2024

Based on application segmentation, Orthopedic Sutures was the leading application in 2024

Based on region, North America was the leading revenue generator in 2024

Drug Integrated Polymer Fibers Market- Segmentation Analysis:

The Global Drug Integrated Polymer Fibers Market is segmented based on Type, Application, Therapeutic Indication, End-User, and Region.

The market is divided into three categories based on Type: Polylactic Acid (PLA), Polydioxanone (PDO), Polycaprolactone (PCL), and Others (PGA, PLGA, and PDLL). Polylactic Acid (PLA) leads the market. Polylactic Acid (PLA), a biodegradable and biocompatible polymer, is frequently used in this market due to its ability to be processed into fibers, films, and other forms for controlled drug release. PLA is derived from renewable resources like cornstarch or sugarcane, making it an eco-friendly choice. Its biodegradability allows for the gradual breakdown of the fibers in the body, minimizing the need for surgical removal.

The market is divided into five categories based on application: Drug Delivery, Orthopedic Sutures, Vascular Stents, Vascular Grafts, Dermal Wound Healing, and Others. Orthopedic Sutures dominate the market. The Drug Integrated Polymer Fibers Market in the Context of Orthopedic Sutures represents a promising and rapidly evolving segment within the medical device industry, combining the biocompatibility of polymer fibers with the need for effective and localized drug delivery in orthopedic applications. Orthopedic sutures made from drug-integrated polymer fibers are designed to promote healing by delivering drugs directly to the surgical site. This is particularly important in orthopedic surgeries, where proper healing of bone and soft tissue is critical for long-term recovery.

The market is divided into three categories based on Therapeutic Indications: Cancer, Cardiovascular Diseases, and Respiratory Diseases. As technology advances, these fibers will become more sophisticated, allowing for better-controlled drug release and personalized treatment approaches, ultimately improving patient outcomes and quality of life. One of the most significant advantages of using polymer fibers for drug delivery in these therapeutic areas is the ability to provide localized and targeted treatment, minimizing systemic side effects. The development of drug-integrated polymer fibers must meet rigorous regulatory requirements, particularly regarding biocompatibility, safety, and long-term efficacy.

The market is divided into two categories based on End-User: Pharmaceutical Companies and Medical Device Manufacturers. The Drug Integrated Polymer Fibers Market, particularly from the perspective of end-users like Pharmaceutical Companies and Medical Device Manufacturers, is experiencing significant growth as these sectors explore advanced drug delivery technologies for more effective and targeted therapies. Both industries are increasingly leveraging drug-integrated polymer fibers to improve patient outcomes and optimize treatment regimens.

Drug Integrated Polymer Fibers Market- Geographical Insights

North America leads the market expansion, primarily driven by the increasing healthcare expenditures in emerging economies. The rise in funding from both government and private sectors for healthcare infrastructure and medical research facilitates the advancement and implementation of drug-integrated polymer fibers. As reported by the American Medical Association, health spending in the United States rose by 4.1% in 2022, reaching USD 4.5 trillion, which translates to USD 13,493 per capita. This growth rate aligns with pre-pandemic figures, specifically 4.1% in 2019. While government expenditures aimed at managing the pandemic resulted in significant increases in National Health Expenditure (NHE), these costs saw a notable decline in 2021, coinciding with a resurgence in the utilization of medical goods and services. Europe ranks as the second-largest region for market growth, attributed to the increasing investments in nanotechnology and electrospinning techniques.

Drug Integrated Polymer Fibers Market- Competitive Landscape:

The Drug Integrated Polymer Fibers Market exhibits a high level of competition, characterized by numerous prominent entities striving to capture market share through the creation of innovative products and sophisticated drug delivery systems. This market is experiencing growth driven by the rising demand for targeted drug delivery mechanisms, minimally invasive medical devices, and biocompatible materials. Firms operating in this sector are dedicated to the development of advanced polymer fibers capable of providing sustained drug release while ensuring the biocompatibility and efficacy of pharmaceuticals. Additionally, these companies are establishing collaborations with pharmaceutical organizations, biotechnology firms, and academic institutions to bolster their product development efforts and gain access to state-of-the-art technologies.

Recent Developments:

On June 25, 2024, Medical products, including ointments and syringes, encountered challenges in providing localized medication delivery, particularly in a controlled manner over extended durations. In response to this issue, researchers at Empa are innovating polymer fibers designed to deliver active ingredients with precision over prolonged periods. These liquid core fibers encapsulate pharmaceuticals and can be integrated into medical textiles.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL DRUG INTEGRATED POLYMER FIBERS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

GLOBAL DRUG INTEGRATED POLYMER FIBERS MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

GLOBAL DRUG INTEGRATED POLYMER FIBERS MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

GLOBAL DRUG INTEGRATED POLYMER FIBERS MARKET, BY THERAPEUTIC INDICATION- MARKET ANALYSIS, 2019 - 2032

GLOBAL DRUG INTEGRATED POLYMER FIBERS MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

GLOBAL DRUG INTEGRATED POLYMER FIBERS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

Table of Contents

1. Drug Integrated Polymer Fibers Market Overview

2. Executive Summary

3. Drug Integrated Polymer Fibers Key Market Trends

4. Drug Integrated Polymer Fibers Industry Study

5. Drug Integrated Polymer Fibers Market: Impact of Escalating Geopolitical Tensions

6. Drug Integrated Polymer Fibers Market Landscape

7. Drug Integrated Polymer Fibers Market - By Type

8. Drug Integrated Polymer Fibers Market - By Application

9. Drug Integrated Polymer Fibers Market - By Therapeutic Indication

10. Drug Integrated Polymer Fibers Market - By End-User

11. Drug Integrated Polymer Fibers Market- By Geography

12. Key Vendor Analysis- Drug Integrated Polymer Fibers Industry

13. 360 Degree AnalystView

14. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â